Connect with us

COVID-19

Pfizer says COVID-19 vaccine will cost $110-$130 per dose

Published

 on

(Last Updated On: October 22, 2022)

Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free.

Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots, AP reported.

The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses.

A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots.

The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to CVS Health, which runs one of the nation’s biggest drugstore chains.

A Pfizer executive said Thursday that the price reflects increased costs for switching to single-dose vials and commercial distribution. The executive, Angela Lukin, said the price was well below the thresholds “for what would be considered a highly effective vaccine.”

The drugmaker said last year that it was charging the U.S. $19.50 per dose, and that it had three tiers of pricing globally, depending on each country’s financial situation. In June, the company said the U.S. government would buy an additional 105 million doses in a deal that amounted to roughly $30 per shot. The government has the option to purchase more doses after that.

Pfizer’s two-shot vaccine debuted in late 2020 and has been the most common preventive shot used to fight COVID-19 in the U.S.

More than 375 million doses of the original vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed in the U.S., according to the Centers for Disease Control and Prevention.

That doesn’t count another 12 million doses of an updated booster that was approved earlier this year.

The vaccine brought in $36.78 billion in revenue last year for Pfizer and was the drugmaker’s top-selling product.

Analysts predict that it will rack up another $32 billion this year, according to FactSet. But they also expect sales to fall rapidly after that.

More than 90% of the adult U.S. population has already received at least one dose of COVID-19 vaccine, according to the CDC. But only about half that population has also received a booster dose.

COVID-19

COVID-19 in Iran: Nearly 900 new cases, 24 deaths recorded

Published

on

(Last Updated On: March 27, 2023)

The Iranian health ministry announced on Sunday that more than 890 new cases of COVID-19 have been identified across the country during the past 24 hours, adding that 24 patients have died in the same period of time, Fars News Agency reported.

“A sum of 891 new patients infected with COVID-19 have been identified in the country based on confirmed diagnosis criteria during the past 24 hours,” the Iranian Health Ministry’s Public Relations Center said on Sunday, adding, “454 patients have been hospitalized during the same time span.”

The ministry’s public relations center said 611 people infected with COVID-19 are in critical condition.

Continue Reading

COVID-19

China says 200 million treated, pandemic ‘decisively’ beaten

Published

on

(Last Updated On: February 17, 2023)

China says more than 200 million of its citizens have been diagnosed and treated for COVID-19 since it lifted strict containment measures beginning in November.

With 800,000 of the most critically ill patients having recovered, China has “decisively beaten” the pandemic, according to notes from a meeting of the ruling Communist Party’s all-powerful Politburo Standing Committee presided over by President and party leader Xi Jinping, AP reported. 

China enforced some of the world’s most draconian lockdowns, quarantines and travel restrictions and still faces questions about the origins of the virus that was first detected in the central Chinese city of Wuhan in late 2019. Heavy-handed enforcement prompted rare anti-government protests and took a heavy toll on the world’s second-largest economy.

The official Xinhua News Agency quoted Xi as saying that policies to control the outbreak had been “entirely correct.” The abrupt lifting in November and December of the “zero COVID” policy that had sought to eliminate all cases of the virus led to a surge in infections that temporarily overwhelmed hospitals.

Case numbers have since peaked and life has largely returned to normal, although international travel in and out of China has yet to return to pre-pandemic levels.

China is now transitioning to a post-pandemic stage after a fight against the outbreak that was “extraordinary in the extreme,” Xinhua said.

The government will continue to “optimize and adjust prevention and control policies and measures according to the times and situations with a strong historical responsibility and strong strategic determination,” Xinhua said.

Continue Reading

COVID-19

Study suggests people who had COVID-19 risk new-onset diabetes

Published

on

(Last Updated On: February 15, 2023)

A new Cedars-Sinai Medical Center suggests that people who have previously been infected with COVID-19 could stand an increased risk for new-onset diabetes.

The study’s results, conducted by researchers at the Smidt Heart Institute at Cedars-Sinai “have confirmed that people who have had COVID-19 have an increased risk for new-onset diabetes — the most significant contributor to cardiovascular disease.”

“Our results validate early findings revealing a risk of developing Type 2 diabetes after a COVID-19 infection and indicate that this risk has, unfortunately, persisted through the Omicron era,” said Dr. Alan Kwan, the author of the study and a cardiovascular physician at Cedars-Sinai.

“The research study helps us understand — and better prepare for — the post COVID-19 era of cardiovascular risk,” he said.

The study also suggests that the risk of Type 2 diabetes appears to be lower in those who had already been vaccinated against COVID-19 prior to their infection.

Continue Reading

Trending

Copyright © 2022 Ariana News. All rights reserved!